Back to News
Market Impact: 0.15
AbbVie To Present Positive Phase 3 Etentamig Data At IMS 2026
Source: Nasdaq
Healthcare & Biotech
AbbVie will present full Phase 3 results for etentamig, an investigational CMA x CD3 bispecific T-cell engager, at the International Myeloma Society Annual Meeting in Glasgow on September 23-26, 2026. The announcement signals an upcoming clinical-data catalyst, but provides no efficacy, safety, or regulatory results.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
ABBV0.30
More News
- Halozyme prices $1.3 billion convertible notes offering
- Jana Partners pushes Cooper to replace CEO, weigh asset sales- WSJ
- FDA approves Ultragenyx’s Fayuvi for Sanfilippo syndrome Type A
- Why is Xenon Pharmaceuticals stock plunging today?
- Intel and Micron lead our portfolio higher, and J&J's strengthens our case for owning it
- Ultragenyx stock surges 10% on FDA approval for gene therapy
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- The $4.7 Trillion Bet: When Does AI Capex Become AI Revenue?
- Equity Research Automation Statistics: A 2026 Evidence Check